Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Hepatitiden

HIV, hepatitis & drug policy reform

HIV, hepatitis & drug policy reform

This report, “HIV, Hepatitis & Drug Policy Reform” follows the Global Commission’s thematic reports on “The War on Drugs and HIV/AIDS” (2012) and “The Negative Impact of the War on Drugs on Public Health: The Hidden Hepatitis C Epidemic” (2013).

Despite a decade-old call for urgent action, current drug control efforts fail, with HIV and hepatitis prevalence persisting among drug users. In 2023, approximately 354 million people around the world are currently living with hepatitis B or C. People who use drugs, especially people who inject drugs, are at a higher risk for blood- borne HIV, hepatitis B and hepatitis C.

Although there has been some success — for example, the scale-up of antiretroviral treatments that reduced HIV related deaths to their lowest in almost three decades — progress has been uneven and people who use drugs are still left behind. This must change. (Global Commission on Drug Policy, 2023)

https://www.globalcommissionondrugs.org/reports/hiv-hepatitis-drug-policy-reform